Organisation paid for research Program year 2025 Source: CMS Open Payments

Miami Research Associates

Neither a doctor nor a teaching hospital

Research payments

$3,827,189

172 payments

Through program year 2025, Miami Research Associates is reported as receiving $3,827,189 in research payments, across 172 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$26,800	1
2024	Research	$1,763	1
2023	Research	$19,401	3
2022	Research	$2,724,307	4
2021	Research	$26,930	5
2020	Research	$300,294	33
2019	Research	$727,695	125

Breakdown

Who paid Research payments · program years 2019–2025

Boehringer Ingelheim International GmbH $2,732,324 3 payments
Janssen Research & Development, LLC $370,954 21 payments
GlaxoSmithKline, LLC. $241,549 64 payments
Catalyst Pharmaceuticals, Inc. $115,631 4 payments
Takeda Pharmaceuticals U.S.A., Inc. $96,754 33 payments
F. Hoffmann-La Roche AG $68,610 10 payments
Novartis Pharmaceuticals Corporation $60,412 4 payments
Ventana Medical Systems, Inc. $51,525 16 payments
Pfizer Inc. $39,017 5 payments
Vanda Pharmaceuticals Inc. $26,800 1 payment

Studies the money was for Research payments · program years 2019–2025

Bioequivalence BI695501 50mg mL vs 100mg mL $2,732,324 3 payments
A Randomized, Double-blind, First-in-Human Phase 1 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health. $288,980 2 payments
RSV Mat-011 $124,876 7 payments
RSV Oa=Adj-002 $85,324 41 payments
Safety,Immunogenicity, and Dose ranging Study of Inactivqatzed Zika Virus vaccine in Healthy Adults $77,849 30 payments
Ocrelizumab in Patients With RMS $68,610 10 payments
A Randomized Subject and Investigator Blinded Placebo Controlled Study to Assess the Safety Pharmacokinetics and Efficacy of Intravenous Bimagrumab in Obese Patients With Type 2 Diabetes $53,263 2 payments
Rd003109 $51,525 16 payments
Long Term Safety Study of Amifampridine Phosphate in Patients With Musk Antibody Positive and Achr (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis $50,163 2 payments
An exploratory, multicenter, placebo-controlled, randomized, double-blind study to investigate the antidepressant mechanism-of-action of JNJ-42847922 in subjects with major depressive disorder. $44,582 16 payments

What the money was spent on Research payments · program years 2019–2025

Other $77,849 30 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.